We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 465.16% and ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...

TD Cowen analyst Steve Scala reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $900.00. The ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

The Baltimore City Board of School Commissioners is suing Eli Lilly and Co., UnitedHealth Group, CVS and several other drug ...

Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn’s ...

Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the revised guidance.